Skip to main content

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors

The Importance of MSI/dMMR as Biomarkers in Oncology
The Importance of MSI/dMMR as Biomarkers in Oncology
By Leonard B. Saltz, MD
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome. Read More ›
Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer
Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer
By Lauren L. Ritterhouse, MD, PhD
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Studies examining the landscape of MSI in various cancers have shown that different tumor types tend to exhibit instability at different microsatellite loci throughout the genome, and a PCR-based test that is limited to the evaluation of only 5 loci may not adequately capture this heterogeneity. Read More ›